Cardio-oncology drug interactions: a scientific statement from the American Heart Association

CJ Beavers, JE Rodgers, AJ Bagnola, TM Beckie… - Circulation, 2022 - Am Heart Assoc
In the cardio-oncology population, drug interactions are of particular importance given the
complex pharmacological profile, narrow therapeutic index, and inherent risk of therapies …

Cancer therapy–associated thrombosis

SP Grover, YM Hisada, RS Kasthuri… - … , and vascular biology, 2021 - Am Heart Assoc
Patients with cancer have an increased risk of both arterial and venous thrombotic events
compared with the general population. Both the site and stage of cancer are known to …

L-asparaginase in the treatment of patients with acute lymphoblastic leukemia

RA Egler, SP Ahuja, Y Matloub - Journal of Pharmacology …, 2016 - journals.sagepub.com
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy that predominantly occurs
in children between 2 and 10 years of age. L-asparaginase is an integral component of …

Asparaginase-associated toxicity in children with acute lymphoblastic leukemia

N Hijiya, IM Van Der Sluis - Leukemia & lymphoma, 2016 - Taylor & Francis
Asparaginase is an integral component of multiagent chemotherapy regimens for the
treatment of children with acute lymphoblastic leukemia. Positive outcomes are seen in …

Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of …

G Kenet, LK Lütkhoff, M Albisetti, T Bernard… - Circulation, 2010 - Am Heart Assoc
Background—The aim of this study was to estimate the impact of thrombophilia on risk of first
childhood stroke through a meta-analysis of published observational studies. Methods and …

[HTML][HTML] Cerebral venous sinus thrombosis

M Capecchi, M Abbattista, I Martinelli - Journal of thrombosis and …, 2018 - Elsevier
The cerebral venous system is an unusual site of thrombosis, with a particularly high
incidence in young adults. This incidence has increased in past decades because of the …

Current use of asparaginase in acute lymphoblastic leukemia/lymphoblastic lymphoma

L Maese, RE Rau - Frontiers in Pediatrics, 2022 - frontiersin.org
Pediatric Acute Lymphoblastic Leukemia (ALL) cure rates have improved exponentially over
the past five decades with now over 90% of children achieving long-term survival. A direct …

The frequency and management of asparaginase‐related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana‐Farber …

RF Grace, SE Dahlberg, D Neuberg… - British journal of …, 2011 - Wiley Online Library
The optimal management of asparaginase‐associated thrombotic complications is not well‐
defined. We report the features, management and outcome of paediatric (ages 0–18 years) …

Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel

W Stock, D Douer, DJ DeAngelo, M Arellano… - Leukemia & …, 2011 - Taylor & Francis
The rapidly increasing use of pegasparaginase (pegASNase) in adults, after a half century
of use of asparaginase (ASNase) in children, has prompted a need for guidelines in the …

Thrombophilia, risk factors and prevention

E Campello, L Spiezia, A Adamo… - Expert review of …, 2019 - Taylor & Francis
Introduction: Fifty-three years after the first description of an inherited prothrombotic
condition (antithrombin deficiency), our knowledge on hereditary and acquired causes of …